Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by indaknownewfieon Apr 20, 2020 3:12pm
93 Views
Post# 30931158

RE:I will

RE:I will
Kingofstockst wrote: Never understand how some ppl here don't see anything wrong with this company, I'm invested in TBP man that company has NR all the time to update shareholders we have q&a with ceo always accessible they have 4 orphan drug designations with FDA, this team never updates us always lies stock price goes only 1 way common ppl can't be this blind... I'm invested in this but how can you not see the problem?????
<br /> <br /> <br />
Hey King. I, like you am heavily in TBP and I love what they do for us as shareholders, but I will tell you this. TBP is the exception rather than the rule. They are probably the best example that the other biotechs should aspire to be. i;m not sure how long you have been investing, not intended to be a slight, but during my time, many biotechs simply do not do NR or engage until they have something to announce. In Kaly;s case , Mr. Farrell is both the CEO and IR. So its possible that he may be preoccupied with solidifying a deal for us so his entire focus /energy is there. It is also entirely possible that we shareholders may be left holding the bag. I hope thats not the case. I want to remain cautiously optimistic that something positive may come of this. So we have three US Patents, one European Patent, Four Orphan Drug Designations, we have marketing exclusivity 7 yrs. For the US, 10 years for Europe. We were recommended for Fast Track Designation and had outstanding Phase 2 clinical results. Now is that reflected in the SP. Not right now but TBP was pushing close to $2 a share about a year ago and a bit and are now hovering around .30 but i believed in its science then and I believe in it now. Likewise. I don't think Kaly is the dead duck many want us to believe. Just trying to provide some perspective. All IMHO and I wish all good luck. 
<< Previous
Bullboard Posts
Next >>